Publications

Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany ABelk, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A et al..  2023.  Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.. J Clin Oncol. 41(7):1470-1491.

Shah MA, Yoshino T, Tebbutt NC, Grothey A, Tabernero J, Xu R-H, Cervantes A, Oh SCheul, Yamaguchi K, Fakih M et al..  2023.  Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.. Clin Colorectal Cancer. 22(1):100-110.

Shah MA, Udrea AAdrian, Bondarenko I, Mansoor W, Sánchez RGuardeño, Sarosiek T, Bozzarelli S, Schenker M, Gomez-Martin C, Morgan C et al..  2022.  Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.. Cancers (Basel). 14(5)

Shah MA, Shitara K, Lordick F, Bang Y-J, Tebbutt NC, Metges J-P, Muro K, Lee K-W, Shen L, Tjulandin S et al..  2022.  Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.. Clin Cancer Res. 28(17):OF1-OF9.

Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim S-B, Tajika M, Lockhart ACraig et al..  2022.  T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.. Future Oncol.

Shah MA, Rogoff HA.  2021.  Implications of reactive oxygen species on cancer formation and its treatment.. Semin Oncol. 48(3):238-245.

Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BChul et al..  2021.  KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.. Future Oncol. 17(10):1143-1153.

Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P et al..  2021.  Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).. J Clin Oncol. 39(9):990-1000.

Shah MA, Mayer S, Emlen F, Sholle E, Christos P, Cushing M, Hidalgo M.  2020.  Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer.. JAMA Netw Open. 3(9):e2023121.

Shah MA, M Emlen F, Shore T, Mayer S, Leonard JP, Rossi A, Martin P, Ritchie E, Niesvizky R, Pastore R et al..  2020.  Hematology and oncology clinical care during the coronavirus disease 2019 pandemic.. CA Cancer J Clin. 70(5):349-354.

Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al..  2020.  Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.